ISSN:
1573-0646
Keywords:
galactitol
;
dianhydrogalactitol
;
cervix
;
non-squamous-chemotherapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00175387
Permalink